Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma
January 3rd 2025Panelists discuss how talquetamab demonstrates superior efficacy compared with physician-chosen treatments for patients with heavily pretreated multiple myeloma, with improved progression-free survival and response rates.
Brief Overview of Therapeutic Landscape for R/R MM
December 19th 2024Panelists discuss how emerging therapies like bispecific antibodies, chimeric antigen receptor (CAR) T cells, and novel drug combinations are reshaping treatment options for patients with relapsed/refractory multiple myeloma (R/R MM) who have exhausted standard approaches.
Treatment Sequencing Strategies for Patients with Relapsed/ Refractory Multiple Myeloma
November 8th 2024Panelists discuss strategies for sequencing bispecific antibodies with B-cell maturation antigen (BCMA)–targeted therapies, considering factors such as prior CAR T-cell treatment, the impact of relapse timing on treatment decisions, and approaches for managing high-risk cytogenetics and extramedullary disease in relapsed/refractory multiple myeloma (R/R MM).
Current Landscape of Relapsed/ Refractory Multiple Myeloma
October 18th 2024Panelists discuss how the current treatment landscape for relapsed/refractory multiple myeloma (R/R MM) includes standard options like such as IMiDs, PIs, and mAbs, while highlighting the emergence of novel therapies such as CAR T- cells and bispecific antibodies, which address unmet needs and offer potential advantages in treatment efficacy and patient outcomes.